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Successful treatment of a brain-metastasized renal cell
carcinoma
Nierenzellkarzinom:ErfolgreicheBehandlungvonMetastasenimGehirn
Abstract
Renal cell carcinoma is an uncommon type of cancer that rarely metas-
tasizes to the brain. The prognosis after discovering brain metastasis
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has traditionally been dismal. We are presenting a case of renal cell
carcinomawithmultiplebrainmetastasesthatwassuccessfullytreated
with multimodal therapy including a new type of medication. 1 Medical Center of Central
Georgia, Macon, GA, USA
Keywords: renal cell carcinoma, brain metastasis, sorafenib
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Institute, Macon, GA, USA Zusammenfassung
Das Nierenzellkarzinom ist eine Karzinomart, die selten in das Gehirn
metastasiert. Die Prognose nach der Entdeckung der Hirnmetastasen
ist gewöhnlich infaust. Wir stellen den Fall eines Nierenzellkarzinoms
mitmultiplenHirnmetastasenvor,dasmiteinermultimodalenTherapie
einschließlich eines neuen Wirkstoffes erfolgreich behandelt worden
ist.
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Successful treatment of a
brain-metastasized renal cell
carcinoma
IntheUnitedStates,renalcellcarcinoma(RCC)accounts
for 2.6% of all cancers, more among men [1]. It rarely
metastasizes to the brain with a median survival after
the diagnosis of brain metastases of 10.7 months and
the 1-year, 2-year, and 5-year survival rates are 48%,
30%,and12%,respectively[2].Wearepresentingacase
of RCC with multiple brain metastases that responded to
neurosurgical, radiation and new drug treatment.
This patient was a 47 year old male who had a two-
months history of numbness on his right side. MRI of the
brain with and without contrast revealed multiple small
enhancing lesions consistent with probable metastatic
disease. The largest lesion was in the left parietal area
(Figure 1). Chest, abdomen and pelvis CT showed a
2.5×1.8cmlesioninhisleftkidney(Figure2).Thepatient
hadnosignificantmedicalhistoryotherthananoperation
for a perforated ulcer 15 years ago. The patient admitted
to smoking a pack and a half of cigarettes a day and
drinking alcohol daily. There were no significant findings
on physical exam. It was decided that the definitive
treatment would depend on pathology and therefore
surgery was undertaken. Pathology showed tubular
structure (Figure 3A, Figure 3B, Figure 3C) with immuno-
reactivitytocytokeratinAE1/AE3(Figure3D)butnegative
for cytokeratin 7 and 20. The histologic features and im-
munoprofile was compatible with renal cell carcinoma.
The patient then had 14 radiation seances to the brain;
after that he was put on the new drug, sorafenib (ap-
proved by the U.S. Food and Drug Administration in
December 2005). The tumor kidney was removed 11
months after metastasis resection. On his followup visit
threeyearslaterthepatientwasneurologicallyintact.He
was on phenytoin and sorafenib. The last MRI, 4 years
after the initial surgery, looks stable without residual or
recurrent tumor.
Figure 1: CT brain showing metastasis in the left parietal area
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Short Communication OPEN ACCESSFigure 2: CT abdomen showing a tumor in the left kidney
Figure 3: Pathologic view of brain metastasis
A: ×4 magnification
B: ×10 magnification
C: Tubular structure (×20)
D: Cytokeratin AE1/AE3 positivity (×10)
This is an illustrative case of a stage IV RCC tumor that
was successfully treated with a multimodal combinatory
approach. Nephrectomy, total or partial, is the first treat-
ment for renal cancer. Metastectomy is usually reserved
for single or limited lesions. In our case, the brain lesions
were multiple. The largest one was not in the motor cor-
tical region so it was deemed resectable. Whole brain
therapy was used to clear microscopic tumor seedings.
A new family of medications called tyrosine protein
kinases inhibitors, namely sunitinib and sorafenib, has
been shown to prolong survival in RCC patients by inter-
fering with angiogenesis. The patient was put on sora-
fenib.Therearefewreportsofrenalcellbrainmetastases
successfully treated with these agents [3], [4]. Sunitinib
is now regarded as the first-line therapy for renal cell
carcinomawhilesorafenibisusedinasecond-linesetting.
Sorafenib has been shown to prevent the growth of tu-
mors but, unlike sunitinib, not to reduce tumor size [5].
Further research is needed to establish the role of
sunitinib and sorafenib in the treatment of brain metas-
tases from renal cancer.
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